BACKGROUND: Lung cancer (LC) is the leading cause of deaths caused by cancer worldwide. A diagnostic test for LC is needed for monitoring high-risk populations. PATIENTS AND METHODS: Fifty-seven markers were measured using multiplex immunoassays of plasma of patients with non-small cell lung cancer (NSCLC); (245 men, 114 women, 1 unknown), asthma (67 men, 111 women, 2 unknown) and of healthy controls (165 men, 122 women, 1 unknown). Mass spectrometry was used for biomarker discovery. A support vector machine (SVM) was used for data analysis. RESULTS: When all biomarkers and both genders were co-analyzed, SVM classified NSCLC and asthma with an accuracy of 0.94. Restricting to NSCLC versus healthy using best subsets of variables (males: epidermal growth factor (EGF), interleukin-8 (IL-8), soluble Fas (sFas), matrix metalloproteinase-9 (MMP-9), plasminogen activator inhibitor-1 (PAI-1); females: EGF, soluble cluster of differentiation 40 (sCD40) ligand, IL-8) yielded sensitivity and specificity of 1. Expression of eleven mass spectrometric biomarkers differed between pathologies. CONCLUSION: Significant inter-pathology and gender differences between biomarkers may improve diagnosis of LC.
BACKGROUND: Lung cancer (LC) is the leading cause of deaths caused by cancer worldwide. A diagnostic test for LC is needed for monitoring high-risk populations. PATIENTS AND METHODS: Fifty-seven markers were measured using multiplex immunoassays of plasma of patients with non-small cell lung cancer (NSCLC); (245 men, 114 women, 1 unknown), asthma (67 men, 111 women, 2 unknown) and of healthy controls (165 men, 122 women, 1 unknown). Mass spectrometry was used for biomarker discovery. A support vector machine (SVM) was used for data analysis. RESULTS: When all biomarkers and both genders were co-analyzed, SVM classified NSCLC and asthma with an accuracy of 0.94. Restricting to NSCLC versus healthy using best subsets of variables (males: epidermal growth factor (EGF), interleukin-8 (IL-8), soluble Fas (sFas), matrix metalloproteinase-9 (MMP-9), plasminogen activator inhibitor-1 (PAI-1); females: EGF, soluble cluster of differentiation 40 (sCD40) ligand, IL-8) yielded sensitivity and specificity of 1. Expression of eleven mass spectrometric biomarkers differed between pathologies. CONCLUSION: Significant inter-pathology and gender differences between biomarkers may improve diagnosis of LC.
Authors: Taofeek K Owonikoko; Mohammad S Hossain; Chandar Bhimani; Zhengjia Chen; Sungjin Kim; Suresh S Ramalingam; Shi-Yong Sun; Dong M Shin; Edmund K Waller; Fadlo R Khuri Journal: Cancer Date: 2013-01-22 Impact factor: 6.860
Authors: Sonia Blanco-Prieto; Lorena Vázquez-Iglesias; Mar Rodríguez-Girondo; Leticia Barcia-Castro; Alberto Fernández-Villar; María Isabel Botana-Rial; Francisco Javier Rodríguez-Berrocal; María Páez de la Cadena Journal: PLoS One Date: 2015-05-18 Impact factor: 3.240
Authors: Sonia Blanco-Prieto; Loretta De Chiara; Mar Rodríguez-Girondo; Lorena Vázquez-Iglesias; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar; María Isabel Botana-Rial; María Páez de la Cadena Journal: Sci Rep Date: 2017-01-24 Impact factor: 4.379
Authors: Sonia Blanco-Prieto; Leticia Barcia-Castro; María Páez de la Cadena; Francisco Javier Rodríguez-Berrocal; Lorena Vázquez-Iglesias; María Isabel Botana-Rial; Alberto Fernández-Villar; Loretta De Chiara Journal: BMC Cancer Date: 2017-12-05 Impact factor: 4.430